Evidence map›Paper›PMID 32811566›Full record

ReviewJournal of experimental & clinical cancer research : CR2020

Aspartate β-hydroxylase as a target for cancer therapy.

Madiha Kanwal, Michal Smahel, Mark Olsen, Jana Smahelova, Ruth Tachezy

Open access · goldAbstract readReview
In one paragraph

Review in Journal of experimental & clinical cancer research : CR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Targeting amino acid in tumor therapy.Frontiers in oncology · 2025
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Madiha KanwalDepartment of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Vestec, Czech Republic.
Michal SmahelDepartment of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Vestec, Czech Republic. smahelm@natur.cuni.cz.ORCID http://orcid.org/0000-0002-0366-4932
Mark OlsenDepartment of Pharmaceutical Sciences, College of Pharmacy - Glendale, Midwestern University, Glendale, AZ, USA.
Jana SmahelovaDepartment of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Vestec, Czech Republic.
Ruth TachezyDepartment of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Vestec, Czech Republic.
Charles University · CZMidwestern University · US

Funding

Ministerstvo Školství, Mládeže a Tělovýchovy LQ1604Ministerstvo Školství, Mládeže a Tělovýchovy LTAUSA18003the European Regional Development Fund CZ.02.1.01/0.0/0.0/16_019/0000785
6 · The paper itself

Abstract

As metastasis is a major cause of death in cancer patients, new anti-metastatic strategies are needed to improve cancer therapy outcomes. Numerous pathways have been shown to contribute to migration and invasion of malignant tumors. Aspartate β-hydroxylase (ASPH) is a key player in the malignant transformation of solid tumors by enhancing cell proliferation, migration, and invasion. ASPH also promotes tumor growth by stimulation of angiogenesis and immunosuppression. These effects are mainly achieved via the activation of Notch and SRC signaling pathways. ASPH expression is upregulated by growth factors and hypoxia in different human tumors and its inactivation may have broad clinical impact. Therefore, small molecule inhibitors of ASPH enzymatic activity have been developed and their anti-metastatic effect confirmed in preclinical mouse models. ASPH can also be targeted by monoclonal antibodies and has also been used as a tumor-associated antigen to induce both cluster of differentiation (CD) 8

Indexed as

Molecular Targeted TherapyAntineoplastic AgentsCalcium-Binding ProteinsHumansLung NeoplasmsMembrane ProteinsMixed Function OxygenasesMuscle ProteinsPrognosisAntineoplastic AgentsASPH protein, humanCalcium-Binding ProteinsMembrane ProteinsMixed Function OxygenasesMuscle ProteinsASPHImmunotherapyMetastasisSmall molecule inhibitor

Identifiers

PMID32811566
PMCPMC7433162
OpenAlexW3065244046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.